A technology has been developed that can double the efficacy duration of glucagon-like peptide-1 (GLP-1) drugs, which have sparked a trend in obesity treatments. It is expected to also reduce the ...
Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.
OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...
OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a ... long-acting ...
(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...
Background: Diabetes mellitus (DM) is a metabolic disorder associated with cognitive impairment. Glucagon-like peptide-1 (GLP-1) and its receptor (GLP-1R) have shown neuroprotective effects. Scope of ...
1 Department of Anatomy, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia 2 Department of Internal Medicine, Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia Introduction: ...
AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...
MIAMI, FLORIDA / ACCESS Newswire / April 1, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback